112 related articles for article (PubMed ID: 22836071)
1. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
Han KH; Rha SW; Kang HJ; Bae JW; Choi BJ; Choi SY; Gwon HC; Bae JH; Hong BK; Choi DH; Han KR
J Clin Lipidol; 2012; 6(4):340-51. PubMed ID: 22836071
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study.
Patel JV; Gupta S; Lie F; Hughes EA
Vasc Health Risk Manag; 2005; 1(4):351-6. PubMed ID: 17315607
[TBL] [Abstract][Full Text] [Related]
3. Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients.
Chamberlin KW; Baker WL
Clin Interv Aging; 2015; 10():733-40. PubMed ID: 25931816
[TBL] [Abstract][Full Text] [Related]
4. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure.
Strey CH; Young JM; Lainchbury JH; Frampton CM; Nicholls MG; Richards AM; Scott RS
Heart; 2006 Nov; 92(11):1603-9. PubMed ID: 16709697
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin induces caspase-mediated apoptotic death through oxidative stress and DNA damage in combined with cisplatin in human cervical cancer cell line.
Hacıseyitoğlu AÖ; Doğan TÇ; Dilsiz SA; Canpınar H; Eken A; Bucurgat ÜÜ
J Appl Toxicol; 2024 Apr; 44(4):623-640. PubMed ID: 38053498
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients.
Kalantari S; Naghipour M
Adv Biomed Res; 2014; 3():168. PubMed ID: 25221771
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia.
Desai NK; Mendelson MM; Baker A; Ryan HH; Griggs S; Boghani M; Yellen E; Buckley L; Gillman MW; Zachariah JP; Graham D; Jonas MM; de Ferranti SD
J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):175-181. PubMed ID: 30334928
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury.
Naiqiong W; Liansheng W; Zhanying H; Yuanlin G; Chenggang Z; Ying G; Qian D; Dongchen L; Yanjun Z; Jianjun L
Med Sci Monit; 2017 Dec; 23():5760-5766. PubMed ID: 29200411
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of alternate-day versus everyday dosing of atorvastatin.
Pramanik S; Das AK; Chakrabarty M; Bandyopadhyay SK; Ghosh M; Dalai CK
Indian J Pharmacol; 2012 May; 44(3):362-5. PubMed ID: 22701247
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin: evidence for its place in treatment of hypercholesterolemia.
Alagona P
Core Evid; 2010; 5():91-105. PubMed ID: 21468365
[TBL] [Abstract][Full Text] [Related]
11. Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial.
Kim M; Kim SE; Lee SM; An WS
J Yeungnam Med Sci; 2024 May; ():. PubMed ID: 38715530
[TBL] [Abstract][Full Text] [Related]
12. Effects of Atorvastatin on Oxidative Stress Biomarkers and Mitochondrial Morphofunctionality in Hyperfibrinogenemia-Induced Atherogenesis.
Scribano Mde L; Baez Mdel C; Florencia B; Tarán MD; Franco S; Balceda AG; Moya M
Adv Med; 2014; 2014():947258. PubMed ID: 26556431
[TBL] [Abstract][Full Text] [Related]
13. Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy.
Lowe RN; Marrs JC; Saseen JJ
Ther Adv Drug Saf; 2013 Feb; 4(1):9-17. PubMed ID: 25083247
[TBL] [Abstract][Full Text] [Related]
14. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
[TBL] [Abstract][Full Text] [Related]
16. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.
Kargiotis K; Katsiki N; Athyros VG; Giouleme O; Patsiaoura K; Katsiki E; Mikhailidis DP; Karagiannis A
Curr Vasc Pharmacol; 2014 May; 12(3):505-11. PubMed ID: 24805248
[TBL] [Abstract][Full Text] [Related]
18. [COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE].
Klyarytskaya IL; Stilidi EI; Maksymova EV
Eksp Klin Gastroenterol; 2015; (7):12-7. PubMed ID: 26817117
[TBL] [Abstract][Full Text] [Related]
19. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
[TBL] [Abstract][Full Text] [Related]
20. Statin use and non-alcoholic steatohepatitis in at risk individuals.
Dongiovanni P; Petta S; Mannisto V; Mancina RM; Pipitone R; Karja V; Maggioni M; Kakela P; Wiklund O; Mozzi E; Grimaudo S; Kaminska D; Rametta R; Craxi A; Fargion S; Nobili V; Romeo S; Pihlajamaki J; Valenti L
J Hepatol; 2015 Sep; 63(3):705-12. PubMed ID: 25980762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
